Conference Coverage

CBC data can predict immunotherapy responses in NSCLC

 

Key clinical point: CBC data can help predict immunotherapy responses and outcomes in non–small cell lung cancer.

Major finding: Hazard ratios for progression-free survival were 1.50 and 1.61 with absolute monocyte count of 0.63 or greater, absolute neutrophil count/absolute lymphocyte of 5.9 or greater at baseline.

Study details: A review of 157 NSCLC cases.

Disclosures: The authors reported having no disclosures.

Source: Soyano AE et al. NCCN poster 075.


 

REPORTING FROM THE NCCN ANNUAL CONFERENCE

– Information readily available on complete blood count can help predict response to immunotherapy and outcomes in patients with advanced non–small cell lung cancer, according to findings from a review of 157 cases.

Specifically, absolute monocyte count of 0.63 or greater and absolute neutrophil count/absolute lymphocyte count of 5.9 or greater at baseline were significantly associated with poor progression-free survival (hazard ratios, 1.50 and 1.61, respectively) and overall survival (HRs, 1.71 and 1.87, respectively) in patients treated with anti–programmed death-1 (PD-1) antibodies, Aixa E. Soyano, MD, reported in a poster at the annual conference of the National Comprehensive Cancer Network.

Additionally, absolute neutrophil count of at least 7.5 and myeloid to lymphoid ratio of at least 11.3 at baseline were associated with poor overall survival (HRs, 1.86 and 2.31, respectively), according to Dr. Soyano of the Mayo Clinic, Jacksonville, Fla.

“The potential predictive value of these readily available biomarkers might help with risk stratification and treatment strategies,” she and her colleagues wrote.

CRP may predict survival after immunotherapy for lung cancer

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge